Drugs / Eprotirome
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT00677248 | Apr → Sep 2008 | hyperlipidemia | Karo Bio AB | Completed | No outcome recorded |
| Phase 2 | NCT00593047 | Nov 2007 → Jul 2008 | hyperlipidemia | Karo Bio AB | Completed | No outcome recorded |
| Phase 2 | NCT00776321 | Sep 2006 → Oct 2007 | hyperlipoproteinemia | Karo Bio AB | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01410383 | Oct 2011 → Oct 2013 | familial hypercholesterolemia | Karo Bio AB | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eprotirome | “thyromimetic compound eprotirome (KB2115) in lowering the level of serum LDL cholesterol in patients with hypercholesterolemia who were already receiving simvastatin or atorvastatin.” PMID 20220185 ↗ Mar 2010 |
| Known as | Bms-356384 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035874 ↗ |
| Known as | Eprotiromo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2035874 ↗ |
| Known as | KB2115 | “Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.” NCT00677248 ↗ |
| Action | Activate | “Thyroid hormone receptor beta-1 agonist” CHEMBL2035874 ↗1“selective thyroid receptor agonist” NCT00593047 ↗ |
| Modality | Small molecule | “thyromimetic compound” PMID 20220185 ↗ Mar 2010 |
| Route | Oral | “tablet formulation given once daily for 12 weeks” NCT00593047 ↗ |
| Target | THRB | “Thyroid hormone receptor beta-1 agonist” CHEMBL2035874 ↗ |